Business Context and Reporting Period
Company: 22nd Century Group, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2012
Business Overview: A plant biotechnology company specializing in genetic engineering to alter nicotine levels in tobacco. The company operates through subsidiaries Hercules Pharmaceuticals (smoking cessation product X-22) and Goodrich Tobacco (premium cigarettes RED SUN and MAGIC). The company is currently in a transition phase from technology licensing to commercializing its own products.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2012 | Six Months Ended June 30, 2011 |
|---|---|---|
| Revenue | $0 | $272,266 |
| Net Loss (Attributable to Common Shareholders) | $(1,980,990) | $(1,753,280) |
| Operating Loss | $(1,821,518) | $(1,723,798) |
| Cash and Cash Equivalents (End of Period) | $2,121 | $86,575 |
| Total Assets | $2,689,810 | $2,388,623 |
| Total Liabilities | $4,694,380 | $3,600,783 |
| Shareholders' Deficit | $(2,004,570) | $(1,212,160) |
| Working Capital | $(2,202,835) | $(1,902,531) |
Debt and Liquidity: The company holds $174,925 in demand bank loans, $617,000 in notes payable, and $1,805,500 in face value of convertible notes (net of discount: $1,243,042). A significant warrant liability of $1,096,200 is recorded on the balance sheet. Cash on hand ($2,121) is insufficient to sustain operations.
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped to zero for the six months ended June 30, 2012, compared to $272,266 in the prior year period. This is due to the completion of a government contract for research cigarettes (SPECTRUM) in late 2011, with no new revenue recognized in the first half of 2012.
- Operating Expenses: General and administrative expenses increased by 46% to $1,361,922, driven primarily by a $372,653 increase in equity-based compensation. Conversely, Research and Development expenses decreased by 59% to $328,998 due to the suspension of clinical trials for the X-22 smoking cessation product.
- Non-Cash Gains: The company recorded a net gain of $632,399 related to warrant liabilities. This gain resulted from a decrease in the fair value of outstanding warrants, partially offset by an immediate charge of $814,500 upon the issuance of new warrants in a May 2012 private placement.
- Interest Expense: Interest expense and amortization of debt discounts surged to $793,327 (up from $31,189) due to the amortization of discounts on convertible notes issued in December 2011 and write-offs associated with partial note conversions.
Guidance, Outlook, Risks, and Unusual Items
- Liquidity Risk: Management explicitly states that cash on hand is insufficient to fund operations or meet obligations as they come due. The company is dependent on raising additional equity financing or securing licensing agreements to continue as a going concern.
- Product Development Status: Clinical trials for X-22 were suspended pending the results of independent trials. The company plans to file applications with the FDA for two modified risk tobacco products (BRAND A and BRAND B) in the second half of 2012. Domestic sales of RED SUN and MAGIC cigarettes are suspended pending a manufacturing agreement with a Master Settlement Agreement participant.
- Unusual Items:
- May 2012 Private Placement: Issued stock and warrants for $1,026,500 total consideration ($786,500 cash). The warrants were valued at $1,841,000, creating an immediate non-cash charge.
- Subsequent Event: On August 9, 2012, the company completed a private placement of $222,600 in convertible notes, receiving $210,000 in cash.
- Legal/Contractual Risks: The company owes approximately $767,000 to North Carolina State University (NCSU) for patent costs and license fees. While NCSU has agreed not to terminate the license until October 15, 2012, failure to pay could result in termination of the exclusive license agreement.
Investor Verification Checklist
- Cash Runway: Verify the company's ability to raise capital immediately, given cash balances of only $2,121 and negative working capital of over $2.2 million.
- Debt Maturities: Review the terms of the $1.8 million in convertible notes due December 16, 2012, and the $350,000 note due July 1, 2012, which is currently in default.
- Warrant Liability Volatility: Monitor the fair value of the $1.09 million warrant liability, which is marked-to-market and significantly impacts reported net income/loss.
- NCSU License Status: Confirm the status of payments owed to NCSU to ensure the exclusive license agreement is not terminated after October 15, 2012.
- Revenue Pipeline: Assess the likelihood of securing a manufacturing partner for RED SUN/MAGIC cigarettes and the timeline for FDA filings for modified risk products.